Evidence map›Paper›PMID 29466296›Full record

ReviewInternational journal of molecular sciences2018

Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.

Gianluca Colella, Flavio Fazioli, Michele Gallo, Annarosaria De Chiara, Gaetano Apice, Carlo Ruosi, Amelia Cimmino, Filomena de Nigris

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gianluca ColellaDivision of Orthopedic Surgery, Department of Human Health, Federico II University of Naples, 80133 Naples, Italy. glc.colella@gmail.com.
Flavio FazioliDivision of Musculoskeletal Oncology Surgery, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy. F.fazioli@istitutotumori.na.it.
Michele GalloDivision of Musculoskeletal Oncology Surgery, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy. miga76@alice.it.
Annarosaria De ChiaraDivision of Pathology, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy. Carlo.ruosi@gmail.com.
Gaetano ApiceDivision of Medical Oncology, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy. anna.dechiara@istitutotumori.na.it.
Carlo RuosiDivision of Orthopedic Surgery, Department of Human Health, Federico II University of Naples, 80133 Naples, Italy. g.apice@istitutotumori.na.it.
Amelia CimminoInstitute of Genetics and Biophysics "A. Buzzati Traverso", National Research Council (CNR), 80131 Naples, Italy. amelia.cimmino@gmail.it.
Filomena de NigrisDepartment of Biochemistry Biophysics and General Pathology, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Filomena.denigris@unicampania.it.ORCID 0000-0002-2322-1557
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITInstitute of Genetics and Biophysics · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment is rapidly evolving toward personalized medicine, which takes into account the individual molecular and genetic variability of tumors. Sophisticated new in vitro disease models, such as three-dimensional cell cultures, may provide a tool for genetic, epigenetic, biomedical, and pharmacological research, and help determine the most promising individual treatment. Sarcomas, malignant neoplasms originating from mesenchymal cells, may have a multitude of genomic aberrations that give rise to more than 70 different histopathological subtypes. Their low incidence and high level of histopathological heterogeneity have greatly limited progress in their treatment, and trials of clinical sarcoma are less frequent than trials of other carcinomas. The main advantage of 3D cultures from tumor cells or biopsy is that they provide patient-specific models of solid tumors, and they overcome some limitations of traditional 2D monolayer cultures by reflecting cell heterogeneity, native histologic architectures, and cell-extracellular matrix interactions. Recent advances promise that these models can help bridge the gap between preclinical and clinical research by providing a relevant in vitro model of human cancer useful for drug testing and studying metastatic and dormancy mechanisms. However, additional improvements of 3D models are expected in the future, specifically the inclusion of tumor vasculature and the immune system, to enhance their full ability to capture the biological features of native tumors in high-throughput screening. Here, we summarize recent advances and future perspectives of spheroid and organoid in vitro models of rare sarcomas that can be used to investigate individual molecular biology and predict clinical responses. We also highlight how spheroid and organoid culture models could facilitate the personalization of sarcoma treatment, provide specific clinical scenarios, and discuss the relative strengths and limitations of these models.

Indexed as

Precision MedicineAnimalsHumansModels, BiologicalSarcomaSpheroids, CellularTumor Cells, CulturedTumor Microenvironmentpersonalized medicineprecision medicinesarcomasspheroidstumor microenvironment

Identifiers

PMID29466296
PMCPMC5855837
OpenAlexW2793050787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.